Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, AstraZeneca Pharma India has informed that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Shikha Mirchandani Chatrath as Director - Commercial Excellence, BD & Strategy with effect from June 17, 2024. In this regard, it has enclosed the details as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, attached as Annexure – A.
The above information is a part of company’s filings submitted to BSE.
